Clinical Trials Logo

Pneumonia clinical trials

View clinical trials related to Pneumonia.

Filter by:

NCT ID: NCT06258603 Completed - Pneumonia Clinical Trials

Oral Care of Intubated Intensive Care Patient

Start date: May 1, 2019
Phase: N/A
Study type: Interventional

The aim of the research was to examine the effect of oral care bundle application on oral health, salivary pH (power of hydrogen), dry mouth and ventilator associated pneumonia in intubated patients compared to standard oral care.

NCT ID: NCT06246994 Not yet recruiting - Pneumonia Clinical Trials

Predictors of Mortality Among Ventilator Associated Pneumonia Patients

Start date: March 2024
Phase:
Study type: Observational

In this context, this study aims to explore the risk factors for mortality from VAP in respiratory ICU.

NCT ID: NCT06243094 Recruiting - Clinical trials for Ventilator Associated Pneumonia

Antibiotic Therapy Practices for Ventilator-Associated Pneumonia (PETUNIA)

PETUNIA
Start date: March 12, 2024
Phase:
Study type: Observational

The French Society of Intensive Care conducts a comprehensive assessment of current antibiotic therapy practices in critically ill patients suspected of Ventilator-Associated Pneumonia (VAP).

NCT ID: NCT06238297 Not yet recruiting - Clinical trials for Pneumonia, Bacterial

Rapid De-escalation of Anti-MRSA Therapy Guided by S. Aureus Nares Screening in Case of Pneumonia

SNAP
Start date: February 10, 2024
Phase: N/A
Study type: Interventional

The current IDSA/ATS guidelines recommend Linezolid and Vancomycin for MRSA coverage in hospitalized patients with pneumonia, which is common clinical practice in Italy. However, a nasal PCR-assay for MRSA has a high negative predictive value and can facilitate rapid antibiotic de-escalation, thereby avoiding unnecessary anti-MRSA treatments. The indiscriminate use of these drugs has contributed to the emergence of resistant S. aureus strains and has led to significant adverse effects, without providing any survival benefits. Additionally, it has increased hospital stays and associated costs. The proposed study aims to use this diagnostic tool to shorten empirical anti-MRSA treatment duration in pneumonia patients, focusing on reducing antimicrobial therapy days while measuring in-hospital mortality, length of stay and adverse drug event incidence.

NCT ID: NCT06229288 Not yet recruiting - Clinical trials for Community-acquired Pneumonia

Amoxicillin Alone Versus Amoxicillin/Clavulanate for Community-acquired Pneumonia in Patients Aged 65 Years or Older, and Hospitalized in a Non-intensive Care Unit Ward

CAPTAIN
Start date: March 15, 2024
Phase: Phase 3
Study type: Interventional

Reduce inappropriate antibiotic use is a priority of public health agencies. Community-acquired pneumonia (CAP) is one of the most important indications for antibiotic prescriptions. In the majority of the studies of CAP, there is a large proportion of cases with no pathogen identified. Thus, the choice of the empirical antibiotic depends on the most likely pathogen, individual risk factors, comorbidities, and allergies. Patients aged 65 years or older are often treated with amoxicillin/clavulanate or with another broad-spectrum antibiotic (third-generation cephalosporins, antipneumococcal fluoroquinolone). However, broad-spectrum antibiotic prescription in CAP is debated and concerns exist about side-effects and selective pressure for resistance. Due to lack of head-to-head antibiotic comparisons, a recent Cochrane review concluded that current evidence from Randomized Clinical Trials (RCTs) is insufficient to make evidence-based recommendations for the choice for antibiotic to be used, highlighting an important evidence gap.

NCT ID: NCT06225258 Recruiting - Pneumonia Clinical Trials

Xanthohumol as an Adjuvant in the Treatment of Septic Shock

Start date: May 9, 2023
Phase: Phase 2
Study type: Interventional

Septic shock (SS) is a life-threatening condition resulting from excessive inflammatory response to bacterial, viral or/and fungal infections. It is associated with dysregulation of the immune system, activation of immune cells, and massive release of cytokines, commonly known as the cytokine storm (CS). The clinical manifestations of SS depend on the initial site of infection. However, the classic symptoms are associated with severe dysfunction of the respiratory and cardiovascular systems, which are observed from the early phase. Respiratory insufficiency frequently requires different forms of oxygen supplementation, including mechanical ventilation and even extracorporeal oxygenation. The severity of respiratory and other organ dysfunction depends on the inflammatory response to the infection and circulating toxins, which correspond to excessive cytokine release. In the past years, several studies documented that reduction of SS-related inflammatory response and CS improved organ function and alleviated the clinical course of SS. Unfortunately, an effective strong anti-inflammatory without side effects medications has not yet been found. Therefore, the use of natural anti-inflammatory and antioxidant substances seems very promising. Xanthohumol (Xn) is a natural prenylated chalcone extracted from the female inflorescences of hop cones (Humulus lupus) and possesses strong anti-inflammatory and antioxidant properties. It is widely used as a supplement to diet. Xanthohumol inhibits CS and has been showed to be an effective medication for reducing the severity of lung injury. It has been documented that Xn inhibits proinflammatory pathways in a different manner. A decrease in cytokine production and release can affect endothelial function and correct inflammatory-related vascular hyperpermeability, reducing uncontrolled water shift to extravascular space and then tissue edema. Clinical observation showed that administration of Xn alleviated clinical course, improved respiratory function, and reduced mortality in critically ill COVID-19 patients. Xanthohumol is safe and well tolerated by humans, and no adverse effects have been reported yet. Based on its strong anti-inflammatory and antioxidative properties, it can be speculated that the use of Xn can effectively reduce the inflammatory response and improve the clinical course in SS patients.

NCT ID: NCT06220019 Not yet recruiting - Clinical trials for Community Acquired Pneumonia

REspiratory diSEAse cohoRt Studies of CHinese Medicine for CAP (RESEARCH- CAP)

Start date: April 2024
Phase:
Study type: Observational

The purpose of this study is to evaluate the clinical efficacy and safety of dialectical treatment in the patients with CAP after discharge in a prospective cohort study: one is the Traditional Chinese Medicine (TCM) cohort, which has been evaluated and has certain effects; The other is a non traditional Chinese medicine queue.

NCT ID: NCT06210737 Completed - Pneumonia Clinical Trials

A Study to Evaluate Persistence of Immunity of PCV13 in Healthy Population Aged 2 Months,7 Months-5 Years

Start date: September 26, 2019
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to learn about persistence of immunity of PCV13 in healthy population aged 2 months, 7 months-5 years. The main questions it aims to answer are the percentage of subjects reached the IgG level of ≥0.35 µg/mL, GMCs level for IgG antibody, and SAEs from one month to 12 months after the last injection.

NCT ID: NCT06210282 Recruiting - Clinical trials for Community Acquired Pneumonia

The Effect of Focused Lung Ultrasonography on Antibiotic Prescribing in General Practice

PLUS-FLUS
Start date: November 3, 2023
Phase: N/A
Study type: Interventional

The goal of this randomised controlled trial is to determine if adults presenting with symptoms of an acute lower respiratory tract infection in general practice where the general practitioner suspects CAP, who have FLUS performed as an addition to usual care, have antibiotics prescribed less frequent compared to those given usual care only.

NCT ID: NCT06206980 Not yet recruiting - Pneumonia Clinical Trials

Promotion of Active Lifestyle in Pneumonia Patients

Start date: January 20, 2024
Phase: N/A
Study type: Interventional

Patients who have suffered a pneumonia used to reduce their activity levels because of the symptoms and the fear to suffer breathlessness. These patients often have sequelae after the hospitalization that previous studies have associated with a lack of physical activity. The main objective of this research is to investigate the efficacy of a rehabilitation program for promotion higher activity levels in quality of life and self-perceived discapacity of pneumonia patients.